PTC Therapeutics agrees to acquire Sangamo ST-920 Fabry assets
PTC Therapeutics agreed to acquire Sangamo assets primarily related to ST-920, an AAV gene therapy product candidate for Fabry disease.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.